MINNEAPOLIS, Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:UBS Global Healthcare ConferenceNovember 12, 20249:30 AM PSTStifel 2024 Healthcare ConferenceNovember 19, 20248:00 AM ESTStephens NASH 2024 ConferenceNovember 20, 202411:00 AM CSTA live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio- ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potenti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIO.B New York Stock Exchange For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTIO ...

Bio-Rad Laboratories, Inc. (BIO) posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year quarter’s level.The quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.The company’s GAAP EPS was $23.34, up 541.2% from ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Â Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Tycho ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $2.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 57.03%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.12 per share when it actually produced earnings of $3.11, delivering a surprise of 46. ...

Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2024 Financial Results HERCULES, Calif.—October 30, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterl ...

MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million. GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostic ...

With the third-quarter earnings season in full swing, it's going to be a pivotal week for numerous firms within the medical device sector. The latest Earnings Preview report indicates strong earnings and revenue growth within the Medical sector. The projected top and bottom-line improvements can be attributed to sustained demand for medical products and services, and favorable pricing strategies, which are likely to offset the shortcomings generated from worldwide geopolitical issues, high-interest expense ...